Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial in multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1393-1395

  Harvey, R Donald ^a   Kaufman, Jonathan L ^a   Johnson, Heather R ^a   Nooka, Ajay ^a   Vaughn, Louette ^b   Flowers, Christopher R ^a   Khoury, H Jean ^a   Lechowicz, Mary J ^a   Langston, Amelia A ^a   Lonial, Sagar ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Hematopoietic stem cell; Mobilization; Multiple myeloma; Pharmacodynamics; Plerixafor; Timing

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ADULT; AGED; APHERESIS; ARTICLE; BONE PAIN; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; MALE; MULTIPLE MYELOMA; NAUSEA; STEM CELL MOBILIZATION; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84882919525     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.06.003     Document Type: Article

References (12)

1. Stewart D.A., Smith C., MacFarland R., Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009, 15:39-46.
2. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. JClin Oncol 2004, 22:1095-1102.
3. Hendrix C.W., Flexner C., MacFarland R.T., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000, 44:1667-1673.
4. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
5. Renfroe H., Arnold M., Vaughn L., et al. Arandomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion 2011, 51:1779-1783.
6. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
7. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
8. Delamain M.T., Marques J.F., de Souza C.A., et al. An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. Transfusion 2008, 48:1133-1137.
9. Sancho J.M., Morgades M., Grifols J.R., et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012, 14:823-829.
10. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
11. Weaver C.H., Birch R., Greco F.A., et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998, 100:338-347.
12. Zeller W., Gutensohn K., Stockschlader M., et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996, 17:709-713.